A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors
Phase: Phase I-II clinical trials
Principal Investigator: Dott.ssa Damian Silvia
Main Facility: Oncologia Medica 1
Drug: ALE.P03
Pathologies: Colorectal cancer (CRC), Lung cancer, Cervical tumor, Urological cancers (kidney, bladder, urinary tract, others)
ClinicalTrials.gov: Read the details about clinical trials
Study designed to assess the safety and efficacy of ALE.P03 (Claudin-1 Targeted Antibody-Drug Conjugate) in monotherapy in adult patients with selected advanced or metastatic CLDN1+ solid tumors.
The study includes two parts: a dose escalation phase (Part I) and a dose expansion phase (Part II) with a selected dose.
Last update: 21/04/2026